Results 221 to 230 of about 100,944 (279)

Discrepant Intracranial and Extracranial Responses to Tarlatamab in Relapsed Small‐Cell Lung Cancer With Untreated Brain Metastases: A Case Report

Respirology Case Reports, Volume 14, Issue 5, May 2026.
A 72‐year‐old man with extensive‐stage SCLC developed untreated brain metastases and was treated with tarlatamab before whole‐brain irradiation. After one cycle, marked shrinkage of extracranial lesions and decreases in tumour markers were observed. By contrast, brain MRI showed progression of intracranial metastases.
Eri Hayashi, Hirohisa Kano, Kayo Nakamura, Takamasa Kondo, Akira Nishioka, Manaya Tanaka, Kotaro Aoe, Shuko Mashimo, Daizo Kishino   +8 more
wiley   +1 more source

Treatment of Steroid-Refractory Immune Checkpoint-Related Hepatitis With Ruxolitinib. [PDF]

ACG Case Rep J
Nguyen VV, Wells M, Moctezuma-Velazquez C, Anaka MR, Walker J, Lytvyak E, Tandon P, Bhanji RA, Montano-Loza AJ.   +8 more
europepmc   +1 more source

Life‐Threatening Prolonged ICANS Following Tarlatamab Treatment in Extensive‐Stage Small Cell Lung Cancer With Brain Metastases: A Case Report

Respirology Case Reports, Volume 14, Issue 5, May 2026.
A patient with extensive‐stage small cell lung cancer developed life‐threatening, prolonged ICANS shortly after tarlatamab treatment. Brain MRI revealed previously unrecognized multiple brain metastases, suggesting a possible link between occult intracranial disease and severe neurotoxicity.
Hiroyuki Arai, Shinji Sasada, Hiroki Kazahari, Yuya Homma, Kyohei Kaburaki   +4 more
wiley   +1 more source

Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy. [PDF]

Cureus
Sharma D, Böhmer W, Kamm CP, Diem L.
europepmc   +1 more source

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response

Reviews in Medical Virology, Volume 36, Issue 3, May 2026.
ABSTRACT Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is
Danya Kaplan, Emily Blyth, Gaurav Sutrave, Michelle K. Yong, David J. Gottlieb, Allison Abendroth, Barry Slobedman, Lauren Stern   +7 more
wiley   +1 more source

Cytokine release syndrome-compatible fever after initiation of local radiotherapy during late-phase epcoritamab therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report. [PDF]

J Pharm Health Care Sci
Nishimura N, Nakashima H, Ogasa Y, Yoshikuni K, Kohno K, Ogawa R.   +5 more
europepmc   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 402-431, May 2026.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

IL6 blockade: an effective approach in steroid-refractory immune checkpoint inhibitor-related neuropathies requiring ICI rechallenge-case report. [PDF]

ESMO Open
Baek C, Kramkimel N, Mélé N, Lenglet T, Psimaras D, Birzu C.   +5 more
europepmc   +1 more source

Elranatamab: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis.
Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Pooneh Soltantabar, Hoi‐Kei Lon, Kamrine Poels, Blerta Shtylla, Donald Irby, Kristin Bompiani‐Myers, Thomas O'Brien, Jennifer Hibma   +10 more
wiley   +1 more source